Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.6% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
11
users have liked this narrative
2
users have commented on this narrative
41
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
0
users have commented on this narrative
14
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.3% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
16
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
908 Devices
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
US Federal And International Funding Will Expand Global Analysis Markets
Key Takeaways Expanding public and private sector funding, along with strong global demand, positions the company for accelerated growth and increased market share in molecular analysis devices. Operational improvements and a shift toward recurring revenue streams are expected to enhance margins, earnings stability, and reduce financial risk.
View narrative
US$10.00
FV
33.7% undervalued
intrinsic discount
5.76%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
1 day ago
author updated this narrative
Coherus Oncology
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Biosimilar Setbacks Will Curb Returns But Slight Hope Endures
Key Takeaways Heavy reliance on a few late-stage products and uncertain clinical outcomes create significant risk for both revenue and earnings sustainability. Downward pricing pressure, biosimilar competition, and slow product uptake threaten long-term profitability despite innovation and new market strategies.
View narrative
US$1.10
FV
4.5% undervalued
intrinsic discount
-51.15%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Cardlytics
AN
AnalystLowTarget
Consensus Narrative from 4 Analysts
Content Restrictions And Concentration Will Curb Performance But Spark Progress
Key Takeaways Heavy reliance on a few major bank partners creates significant vulnerability to revenue loss and partner-specific disruptions. New partnerships and innovations are slow to offset recent setbacks, while stricter data rules and underinvestment threaten future growth and profitability.
View narrative
US$1.50
FV
19.3% undervalued
intrinsic discount
-13.37%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Hexagon Purus
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Green Hydrogen Delays Will Dampen Market Potential Amid Battery Competition
Key Takeaways Overreliance on government incentives and slow hydrogen infrastructure adoption threaten revenue stability, while intensifying battery-electric competition challenges long-term market potential. High R&D spending, ongoing restructuring, and volatile industry conditions undermine profitability and risk further shareholder dilution without margin or cash flow improvement.
View narrative
NOK 1.70
FV
5.9% overvalued
intrinsic discount
17.32%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
SoundThinking
AN
AnalystLowTarget
Consensus Narrative from 6 Analysts
Municipal Budget Constraints Will Hurt Momentum But Spark Cautious Optimism
Key Takeaways Legislative uncertainty, budget constraints, and concentration risk could impede the adoption of new products and create unpredictable revenue growth across targeted sectors. Investments in AI and international expansion offer growth potential but pose risks of elevated costs, delayed revenue, privacy concerns, and limited long-term market penetration.
View narrative
US$19.00
FV
32.8% undervalued
intrinsic discount
7.38%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Biodesix
AN
AnalystLowTarget
Consensus Narrative from 4 Analysts
Lung Diagnostics Will Face Regulatory Delays While Modest Progress Unfolds
Key Takeaways Operational and reimbursement hurdles may restrict revenue growth and margin expansion despite efforts to widen adoption and capitalize on innovative diagnostic trends. Competitive threats and shifting technology demands require sustained investment, raising compliance and R&D costs while heightening risks to long-term profitability.
View narrative
US$1.50
FV
73.6% undervalued
intrinsic discount
18.80%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Alector
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Overvaluation Will Deflate Prospects In A Niche Neurology Market
Key Takeaways Alector's limited target market and intense pricing pressures threaten future revenue growth and profit potential, even with successful regulatory outcomes. Persistent financial losses and competition from larger biotech firms increase risks of dilution, delays, and challenges in attracting resources and partnerships.
View narrative
US$1.00
FV
125.0% overvalued
intrinsic discount
-43.27%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Inseego
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Fierce Pricing Battles And Commoditized Hardware Will Erode Standalone Relevance
Key Takeaways Intense competition and industry shifts toward integrated solutions threaten Inseego's market relevance, margins, and long-term earnings stability. Heavy dependence on a few customers and slow progress in transitioning to recurring software revenue expose the company to volatile growth and margin risk.
View narrative
US$8.00
FV
7.6% overvalued
intrinsic discount
4.43%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Clarus
AN
AnalystLowTarget
Consensus Narrative from 6 Analysts
Digital Shifts And Pricing Wars Will Compress Margins
Key Takeaways Shifting consumer preferences and adverse weather trends challenge Clarus' core market, risking stagnant sales and reduced demand for its key outdoor brands. Intensifying price competition, regulatory costs, and niche brand dependence threaten margins and long-term earnings, increasing risks of underperformance and weak cash flow.
View narrative
US$3.00
FV
13.0% overvalued
intrinsic discount
4.17%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Value any company in seconds
Popular companies